Solid-phase extraction enhances detection of beta-amyloid peptides in plasma and enables Aβ quantification following passive immunization with Aβ antibodies

Journal of Neuroscience Methods

Volumn 169, Issue 1, 2008, Pages 16-22

  Lanz, Thomas A ^a   Schachter, Joel B ^a  

^a PFIZER INC   (United States)

Author keywords

ELISA; Passive immunization; Plasma A ; Solid phase extraction

Indexed keywords

AMYLOID BETA PROTEIN;

ARTICLE; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNOASSAY; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; SOLID PHASE EXTRACTION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; ANTIBODIES, MONOCLONAL; BRAIN; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOTHERAPY; MICE; MICE, TRANSGENIC; NEUROCHEMISTRY; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; SOLID PHASE EXTRACTION; TREATMENT OUTCOME; UP-REGULATION;

EID: 39749198435     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2007.11.009     Document Type: Article

References (20)

1. Asami-Odaka A., Obayashi-Adachi Y., Matsumoto Y., Takahashi H., Fukumoto H., Horiguchi T., et al. Passive immunization of the Abeta42(43) C-terminal-specific antibody BC05 in a mouse model of Alzheimer's disease. Neurodegener Dis 2 (2005) 36-43
2. Bitan G., Fradinger E.A., Spring S.M., and Teplow D.B. Neurotoxic protein oligomers-what you see is not always what you get. Amyloid 12 (2005) 88-95
3. DeMattos R.B., Bales K.R., Cummins D.J., Dodart J.C., Paul S.M., and Holtzman D.M. Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 98 (2001) 8850-8855
4. Du Y., Dodel R., Hampel H., Buerger K., Lin S., Eastwood B., et al. Reduced levels of amyloid beta-peptide antibody in Alzheimer disease. Neurology 57 (2001) 801-805
5. Glenner G.G., and Wong C.W. Alzheimer's disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120 (1984) 885-890
6. Gray A.J., Sakaguchi G., Shiratori C., Becker A.G., LaFrancois J., Aisen P.S., et al. Antibody against C-terminal Abeta selectively elevates plasma Abeta. Neuroreport 18 (2007) 293-296
7. Hepler R.W., Grimm K.M., Nahas D.D., Breese R., Dodson E.C., Acton P., et al. Solution state characterization of amyloid beta-derived diffusible ligands. Biochemistry 45 (2006) 15157-15167
8. Holtzman D.M., Bales K.R., Paul S.M., and DeMattos R.B. Abeta immunization and anti-Abeta antibodies: potential therapies for the prevention and treatment of Alzheimer's disease. Adv Drug Deliv Rev 54 (2002) 1603-1613
9. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., et al. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 274 (1996) 99-102
10. Kuo Y.M., Kokjohn T.A., Kalback W., Luehrs D., Galasko D.R., Chevallier N., et al. Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun 268 (2000) 750-756
11. Lanz T.A., and Schachter J.B. Demonstration of a common artifact in immunosorbent assays of brain extracts: development of a solid-phase extraction protocol to enable measurement of amyloid-beta from wild-type rodent brain. J Neurosci Methods 157 (2006) 71-81
12. Lanz T.A., Karmilowicz M.J., Wood K.M., Pozdnyakov N., Du P., Piotrowski M.A., et al. Concentration-dependent modulation of amyloid-beta in vivo and in vitro using the gamma-secretase inhibitor LY-450139. J Pharmacol Exp Ther 319 (2006) 924-933
13. Mehta P.D., Dalton A.J., Mehta S.P., Kim K.S., Sersen E.A., and Wisniewski H.M. Increased plasma amyloid beta protein 1-42 levels in Down syndrome. Neurosci Lett 241 (1998) 13-16
14. Mehta P.D., Pirttila T., Mehta S.P., Sersen E.A., Aisen P.S., and Wisniewski H.M. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch Neurol 57 (2000) 100-105
15. Moir R.D., Tseitlin K.A., Soscia S., Hyman B.T., Irizarry M.C., and Tanzi R.E. Autoantibodies to redox-modified oligomeric Abeta are attenuated in the plasma of Alzheimer's disease patients. J Biol Chem 280 (2005) 17458-17463
16. Mruthinti S., Buccafusco J.J., Hill W.D., Waller J.L., Jackson T.W., Zamrini E.Y., et al. Autoimmunity in Alzheimer's disease: increased levels of circulating IgGs binding Abeta and RAGE peptides. Neurobiol Aging 25 (2004) 1023-1032
17. Schoonenboom N.S., Mulder C., Van Kamp G.J., Mehta S.P., Scheltens P., Blankenstein M.A., et al. Amyloid beta 38, 40 and 42 species in cerebrospinal fluid: more of the same?. Ann Neurol 58 (2005) 139-142
18. Simonsen A.H., Hansson S.F., Ruetschi U., McGuire J., Podust V.N., Davies H.A., et al. Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods. Dement Geriatr Cogn Disord 23 (2007) 246-250
19. Slemmon J.R., Painter C.L., Nadanaciva S., Catana F., Cook A., Motter R., et al. Distribution of Abeta peptide in whole blood. J Chromatogr B Anal Technol Biomed Life Sci 846 (2007) 24-31
20. Wang J., Dickson D.W., Trojanowski J.Q., and Lee V.M. The levels of soluble versus insoluble brain Abeta distinguish Alzheimer's disease from normal and pathologic aging. Exp Neurol 158 (1999) 328-337